Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + gefitinib + ibandronic acid + icotinib + zoledronic acid
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination of three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (erlotinib, gefitinib, and icotinib) and two bisphosphonates (ibandronic acid and zoledronic acid). The EGFR inhibitors work by blocking the activity of the EGFR tyrosine kinase domain, preventing cell growth and proliferation in cancer cells that overexpress EGFR. The bisphosphonates work by inhibiting osteoclast function and preventing bone resorption, which can help manage bone metastases and hypercalcemia associated with cancer.
02
Targets
EGFR (Epidermal growth factor receptor)FDPS (Farnesyl pyrophosphate synthase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on erlotinib + gefitinib + ibandronic acid + icotinib + zoledronic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + gefitinib + ibandronic acid + icotinib + zoledronic acid.